Table 1.
Baseline characteristics of randomized subjects with elevated or normal transaminases
| Variable | ALT or AST > 30 U/L (n = 516) | ALT or AST ≤ 30 U/L (n = 290) | P-value |
|---|---|---|---|
| Demographic | |||
| Age (y) | 47.6 ± 7.4 | 47.6 ± 7.6 | 0.98 |
| Male % | 92 | 72 | < 0.0001 |
| Race % | 0.0003 | ||
| White | 80 | 69 | |
| Black | 10 | 19 | |
| Asian | 1 | 1 | |
| Hispanic | 8 | 10 | |
| Other | 2 | 1 | |
| Hepatitis C % | 10 | 7 | 0.09 |
| Any viral hepatitis % | 25 | 17 | 0.006 |
| Testosterone % | 24 | 13 | < 0.0001 |
| Lipid-lowering therapy % | 48 | 40 | 0.03 |
| Immunologic | |||
| CD4 (cells/mm3) | 611 ± 303 | 579 ± 264 | 0.13 |
| Undetectable viral load % | 77 | 77 | 0.33 |
| ART % | 0.04 | ||
| NRTI alone | 5 | 4 | |
| NRTI + NNRTI | 35 | 30 | |
| NRTI + PI | 42 | 52 | |
| NRTI + NNRTI + PI | 11 | 7 | |
| Other | 7 | 6 | |
| Metabolic | |||
| BMI (kg/m2) | 28.9 ± 3.9 | 29.2 ± 4.8 | 0.44 |
| VAT (cm2) | 191 ± 83 | 167 ± 83 | < 0.0001 |
| SAT (cm2) | 214 ± 112 | 263 ± 136 | < 0.0001 |
| Fat in limbs (kg) | 6.6 ± 3.9 | 8.7 ± 5.1 | < 0.0001 |
Mean ± SD
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; BMI, body mass index; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue.